红外肝病治疗仪联合恩替卡韦及乙肝抗纤汤治疗老年慢性乙型肝炎的疗效  

Efficacy of Infrared Hepatopathy Therapeutic Instrument Combined with Eentecavir and Anti-fibrosis Decoction in the treatment of Chronic Hepatitis B in Older Patients

作　　者：史娜[1] 宋娟丽 王静[1] 尹玉红 商宁[1] Shi Na;Song Juanli;Wang Jing;Yin Yuhong;Shang Ning(Handan Infectious Disease Hospital,Handan 056002,China;Handan Central Hospital,Handan 056002,China;Community Health Service Center of Heping Street,Congtai District,Handan 056002,China)

机构地区：[1]邯郸市传染病医院,中国邯郸056002 [2]邯郸市中心医院,中国邯郸056002 [3]邯郸市丛台区和平街道社区卫生服务中心,中国邯郸056002

出　　处：《国际老年医学杂志》2020年第5期322-325,共4页International Journal of Geriatrics

基　　金：邯郸市科技局科学计划项目(1723208006ZC)。

摘　　要：目的研究红外肝病治疗仪联合恩替卡韦及乙肝抗纤汤治疗老年慢性乙型肝炎的临床疗效。方法选取2015年8月~2016年8月邯郸市传染病医院收治的76例老年慢性乙型肝炎(下简称乙肝)患者,根据治疗方法分为对照组与实验组,各38例。对照组给予恩替卡韦及乙肝抗纤汤治疗3个月,实验组在此基础上使用红外肝病治疗仪照射3个月。比较治疗前后肝功能指标(ALT、AST、TBiL)、肝纤维化指标(HA、LN、PC-Ш、Ⅳ-C)、乙型肝炎e抗原(HBeAg)、乙型肝炎病毒DNA(HBV-DNA)转阴率、炎性因子水平(IL-2、IL-6、IL-8、TNF-α、IL-1β、IFN-γ)及临床症状好转率。结果治疗3个月后,实验组临床症状好转率明显高于对照组(P<0.05);两组肝功能指标(ALT、AST、TBiL)、肝纤维化指标(HA、LN、PC-Ш、Ⅳ-C)、炎性因子(IL-2、IL-6、IL-8、TNF-α、IL-1β、IFN-γ)水平较治疗前显著降低,且实验组明显低于对照组(P<0.05);实验组HBeAg、HBV-DNA转阴率显著高于对照组(P<0.05)。结论红外肝病治疗仪与恩替卡韦及乙肝抗纤汤联用具有更好的临床疗效,可降低肝脏纤维化水平,并有效调节炎症因子水平,值得临床推广和应用。Objective To study the efficacy of infrared hepatopathy therapeutic instrument combined with entecavir and anti-fibrosis decoction in the treatment of chronic hepatitis B in older patients.Methods 76 older patients with chronic hepatitis B were selected from August 2015 to August 2016 in Handan Infectious Disease Hospital.The patients were divided into the control group(38 cases)and the experimental group(38 cases)according to the treatment methods.The control group was treated with entecavir and anti-fibrosis decoction for 3 months.The experimental group was treated with infrared hepatopathy therapeutic instrument,entecavir and anti-fibrosis decoction for 3 months.The liver function indexes(ALT,AST,TBiL),liver fibrosis indexes(HA,LN,PC-Ⅲ,Ⅳ-C),HBeAg,HBV-DNA,the levels of inflammatory factors(IL-2,IL-6,IL-8,TNF-α,IL-1β,IFN-γ),and the clinical symptoms were compared between the two groups.Results After 3 months of treatment,the improvement of clinical symptoms in the experimental group was better than that in the control group(P<0.05).After treatment,the levels of liver function indexes(ALT,AST,TBiL),liver fibrosis indexes(HA,LN,PC-Ⅲ,Ⅳ-C)and inflammatory factors(IL-2,IL-6,IL-8,TNF-α,IL-1β,IFN-γ)of two groups were significantly decreased,and were significantly lower in the experimental group than those in the control group(P<0.05).The clearance rates of HBeAg and HBV-DNA in the experimental group were significantly higher than those in the control group(P<0.05).Conclusion Infrared hepatopathy instrument combined with entecavir and anti-fibrosis decoction demonstrates a good clinical response by reducing the liver fibrosis and regulating the inflammatory factors.

关 键 词：红外肝病治疗仪 恩替卡韦 乙肝抗纤汤 老年慢性乙肝 纤维化 炎性因子 

分 类 号：R512.62[医药卫生—内科学]